Remdesivir: The Six-Day Window

Six days. That is how long it took, between the moment the world's leading public health agency accidentally let slip that remdesivir didn't work and the moment Anthony Fauci stood at the Oval Office podium and declared that it did. Six days in which a primary endpoint was rewritten. Six days in which a drug that had been pulled from an Ebola trial for inferiority became, by Presidential proclamation, "a new standard of care" for COVID-19. And from those six days, an entire architecture of federal payments, hospital protocols, and regulatory immunity was built that would, by Gilead Sciences' own accounting, deliver the drug to roughly one in two hospitalized COVID patients in the United States.

This is the first in a seven-part investigative series. Before us is the question that will run through every part: how a system designed to protect patients was used, with documented financial inducement, to administer an experimental product to hundreds of thousands of Americans without telling them they had the right to refuse.

Remdesivir is the place to begin because the documentary record is unusually clean. The peer-reviewed trial findings are public. The FDA's Letter of Authorization is public. The Federal Register entries establishing the financial architecture are public. The pharmacovigilance signals are public. The wrongful death complaints are public. The court rulings are public. There is no need for speculation. The story is already written in the official record. We need only to read it carefully.

What follows is that careful reading.

---

The Drug That Couldn't Save Lives in Africa

To understand what happened in April 2020, you must first understand what was already known about remdesivir before the COVID-19 pandemic began. The drug — originally developed by Gilead Sciences with substantial U.S. taxpayer funding — had a documented track record of failure.

In 2018 and 2019, remdesivir was tested in the PALM trial in the Democratic Republic of the Congo against the Ebola virus. The trial compared four therapies. Remdesivir was dropped from the trial in August 2019 because two other treatments — REGN-EB3 and the monoclonal antibody mAb114 — substantially outperformed it. Mortality in the remdesivir arm of the Ebola trial reached 53 percent. Elevated markers for liver and kidney damage were documented during the trial. The drug was, in the most charitable framing, inferior. In the less charitable framing, it was being eliminated for safety as well as efficacy reasons.

This was the drug's last clinical exposure of meaningful scale before the COVID-19 pandemic. By any objective scientific measure, remdesivir entered 2020 as a compound that had been tested against a serious viral disease, found to underperform, and removed from active investigation. It was not, in early 2020, a promising therapeutic looking for a new application. It was a candidate that had failed and was being held in reserve.

Then came COVID.

The federal investment that purchased nothing

According to the U.S. Government Accountability Office's published report Biomedical Research: Information on Federal Contributions to Remdesivir (GAO-21-272, March 31, 2021), federal agencies including the National Institutes of Health, the Centers for Disease Control and Prevention, and the Department of Defense had between 2013 and 2020 conducted preclinical research collaborations with Gilead and provided approximately $162 million in federal funding for the drug's development. Public Citizen's independent analysis put the figure of direct taxpayer contribution to development at approximately $70.5 million.

For all of that public investment, the federal government secured no patent rights. It negotiated no royalty interest. When remdesivir would later generate $2.8 billion in 2020 revenue and $5.6 billion in 2021 revenue for Gilead, the U.S. Treasury would receive no return on its investment beyond ordinary corporate tax. The intellectual property was Gilead's. The price was Gilead's to set. The American taxpayer had funded the laboratory work, and Gilead had funded the patent attorneys.

By May 2020, Reps. Lloyd Doggett and Rosa DeLauro would write a formal letter to the Department of Health and Human Services demanding an accounting of these contributions. The accounting would not change the structure that had already been put in place. By that point, the EUA was issued and the federal payment architecture was being assembled.

---

The Six Days

The story of how remdesivir came to be the federally favored COVID-19 treatment is not a story of years or months. It is a story of six days in late April 2020. To understand it, the timeline must be read with care.

That is the six-day window. What had been one trial showing failure and another trial that, at its original endpoint, would have shown the same, became overnight a federally endorsed therapeutic with a Letter of Authorization, a Patient Fact Sheet, and the moral authority of a Presidential announcement behind it.

The endpoint change is the documentary fingerprint. It is sitting on ClinicalTrials.gov for anyone to see. The protocol revision history is public. Independent academic critics — including Peter Doshi writing in the British Medical Journal, and biostatisticians at multiple academic institutions — have flagged it. The change happened. The mortality data went into the secondary outcomes, where they did not need to reach statistical significance to justify the announcement that followed.

---

The Consent Architecture That Was Designed and the Consent Architecture That Was Used

The Patient Fact Sheet that the FDA issued on May 1, 2020 is a remarkable document, not for what it says but for the fact that it exists at all. To understand its function, the statute that authorized it must be read with attention.

Section 564 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3, governs every Emergency Use Authorization the FDA issues. Subsection (e)(1)(A)(ii) requires that the Secretary establish:

Appropriate conditions designed to ensure that individuals to whom the product is administered are informed — (I) that the Secretary has authorized the emergency use of the product; (II) of the significant known and potential benefits and risks of such use, and of the extent to which such benefits and risks are unknown; and (III) of the option to accept or refuse administration of the product, of the consequences, if any, of refusing administration of the product, and of the alternatives to the product that are available and of their benefits and risks.21 U.S.C. § 360bbb-3(e)(1)(A)(ii)

The phrase that matters is the third one: the option to accept or refuse. Congress, in writing this statute, made a deliberate decision that any patient given an unapproved emergency-use product had a federal statutory right to be told they could say no. The right was not buried in the structure. It was named explicitly as a condition of authorization itself. Without it, the authorization is incomplete.

The statute provides for waiver of the consent condition only in narrow circumstances. The President may waive the option-to-refuse requirement only in cases involving the administration of an EUA product to members of the armed forces, and only by written determination that compliance is "not in the interests of national security." 21 U.S.C. § 360bbb-3(e)(2). No such Presidential waiver was issued for remdesivir. None was issued for any aspect of the COVID-19 response involving civilian patients. The statutory floor of voluntary consent was, in legal terms, intact for the entire period.

The Patient Fact Sheet

The FDA Fact Sheet for Patients and Caregivers (FDA Media File 143190), published the same day the EUA was issued, contains the operative communication by which the FDA fulfilled the statutory consent condition. The Fact Sheet's language is plain:

Receiving remdesivir may benefit certain people in the hospital with COVID-19. Read this Fact Sheet for information about remdesivir. Talk to your healthcare provider if you have questions. It is your choice to receive remdesivir or stop it at any time.

The Healthcare Provider Fact Sheet (FDA Media File 137565), issued the same day, conditioned authorized administration on the prescriber having confirmed that the patient or caregiver "has been given the Fact sheet, informed that remdesivir is an unapproved drug authorized for use under EUA, given information on alternatives and their risks and benefits, and the patient/caregiver has the right to refuse or accept."

This was the consent architecture as designed. It was a federal statutory floor of voluntary, informed acceptance, operationalized through two specific documents that the FDA itself produced and made available.

The consent architecture as used

What hospitals actually did with this architecture is documented in the wrongful death complaints filed in state and federal courts across the country since 2022. The pattern is consistent. Patients were admitted to hospitals with COVID-19 symptoms. They signed general admission consent forms — the broad authorization-to-treat documents that are routine at hospital admission and that, by their nature, cannot disclose the specific risks of a medication that has not yet been prescribed. They were administered remdesivir. They were not given the Patient Fact Sheet. They were not told that the drug was unapproved and authorized only for emergency use. They were not told that they had a federal statutory right to refuse it.

In Briones v. Kaiser Permanente Riverside, filed in California in September 2022, the complaint alleges remdesivir was administered without informed consent and that the plaintiff was not told about alternatives. In Casale v. Mountain View Hospital, filed in Nevada in December 2022, the family alleges that a patient stable on BiPAP deteriorated within days of remdesivir administration and died of renal failure, septic shock, and hypoxic respiratory failure — without ever having been told that remdesivir's documented adverse-event profile included exactly those outcomes. In Schara v. Ascension Wisconsin, tried before a jury in Wisconsin in June 2025, the family alleged remdesivir was administered together with sedation and improper Do Not Resuscitate orders in a manner that effectively foreclosed the family's ability to intervene. In Charles v. Northwell Health — the case currently pending in the Supreme Court of the State of New York, Nassau County — the family of Danielle Cathleen Alvarez, a nineteen-year-old who entered the hospital with stable COVID-19 symptoms, alleges that she received remdesivir for a course twice the standard duration, was given tocilizumab, was intubated, and died after a forty-one-day hospitalization, without the FDA Fact Sheet ever having been provided.

The legal cases share a common factual allegation: the federal Patient Fact Sheet, on which the lawful authorization of remdesivir depended, was not given to the patient or family. The federal statutory right to refuse, which Section 564 expressly required the FDA to ensure, was not communicated.

---

The Money: How a Failed Drug Became a Hospital Profit Center

If the Patient Fact Sheet existed and was nevertheless not delivered to patients, the question is why. The answer is found in the Federal Register and the public filings of the Centers for Medicare and Medicaid Services. The federal government did not merely permit hospitals to administer remdesivir. It paid them — substantially, structurally, and specifically — to do it.

The CARES Act Section 3710 adjustment

Section 3710 of the Coronavirus Aid, Relief, and Economic Security Act, signed into law on March 27, 2020, directed the Secretary of Health and Human Services to "increase the weighting factor of the assigned Diagnosis-Related Group by 20 percent" for individuals diagnosed with COVID-19. Coronavirus Aid, Relief, and Economic Security Act § 3710, Pub. L. No. 116-136 (2020). In ordinary Medicare billing, hospital reimbursement is calculated by reference to the DRG — a coded category that bundles the typical cost of treating a particular condition. The CARES Act took the standard DRG payment for any patient diagnosed with COVID-19 and increased it by twenty percent.

Per Kaiser Family Foundation analysis, the average Medicare payment per COVID-19 hospitalization was approximately $23,000 for traditional Medicare beneficiaries — a figure that includes the twenty percent CARES adjustment. For severely ill patients on mechanical ventilation, the figure rose to approximately $40,000.

The NCTAP add-on

On November 2, 2020 — eleven days after the FDA granted full approval to remdesivir, and twelve days after the World Health Organization's Solidarity Trial released interim results showing the drug had no significant mortality benefit — the Centers for Medicare and Medicaid Services implemented the New COVID-19 Treatments Add-on Payment ("NCTAP") through Interim Final Rule CMS-9912-IFC, published in the Federal Register at 85 Fed. Reg. 71142 (November 6, 2020).

The NCTAP was an additional payment, layered on top of the CARES Act twenty percent adjustment. Its formula provided for an enhanced reimbursement equal to the lesser of sixty-five percent of the operating outlier threshold for the claim or sixty-five percent of the case costs exceeding the standard DRG payment. The eligibility condition was the use of an FDA-approved or EUA-authorized COVID-19 treatment. At the moment the rule was issued, only two products qualified for the NCTAP: remdesivir and convalescent plasma.

What this meant in operational terms is that the federal government created a payment specifically for the use of remdesivir (and one other product) and made it conditional on hospital administration of the drug. A hospital that admitted a Medicare patient with COVID-19 received the standard DRG payment plus the twenty percent CARES adjustment. If that hospital additionally administered remdesivir, it received a further enhanced payment under the NCTAP. The structure was, in functional terms, a per-administration federal subsidy for remdesivir.

The NCTAP remained in effect through September 30, 2023.

What Gilead made

According to Gilead Sciences' Securities and Exchange Commission filings, the remdesivir-branded product Veklury generated approximately $2.8 billion in sales in calendar year 2020 and an additional $5.6 billion in sales in calendar year 2021 — a total of more than $8 billion in two years from a drug that had been pulled from an Ebola trial fifteen months earlier for inferiority. Per Axios reporting on Gilead's filings, the gross profit margin on remdesivir government sales approached ninety percent. By January 2021, Gilead's chief executive officer Daniel O'Day reported publicly that approximately fifty percent of hospitalized COVID-19 patients in the United States were receiving Veklury.

Read the bottom row first. That is the structural answer to the question of who benefited and who paid. The patient is at the bottom of the ledger, listed not as a recipient of benefit but as a unit of measurement — the "covered countermeasure" administration that triggered the payments above.

---

The International Evidence the United States Did Not Honor

The federal financial architecture was finalized on November 2, 2020, with the publication of the NCTAP Interim Final Rule. The implementation date was eleven days after the FDA had granted full approval to remdesivir on October 22, 2020. The full approval decision had itself come precisely seven days after the World Health Organization's Solidarity Trial released its interim findings on October 15, 2020.

The Solidarity Trial deserves careful attention because it was, by design and execution, the largest randomized controlled trial of COVID-19 therapeutics ever conducted. It enrolled 14,221 patients across 454 hospitals in 35 countries. WHO Solidarity Trial Consortium, Repurposed Antiviral Drugs for COVID-19, 384 N. Engl. J. Med. 497 (December 2, 2020). Its final results, published in The Lancet in May 2022, reported overall mortality of 14.5 percent in the remdesivir group versus 15.6 percent in the control group — a rate ratio of 0.91 with a 95 percent confidence interval of 0.82 to 1.02 and a p-value of 0.12. The finding was not statistically significant. For patients already on mechanical ventilation, mortality was higher in the remdesivir arm: 42.1 percent versus 38.6 percent in the control arm.

On November 20, 2020 — eighteen days after the United States implemented the NCTAP payment — the World Health Organization issued a conditional recommendation against the use of remdesivir in hospitalized COVID-19 patients regardless of disease severity. World Health Organization, Therapeutics and COVID-19: Living Guideline (November 20, 2020).

The WHO recommendation against the drug should have been the inflection point. It was the conclusion of the largest international trial ever conducted. It was issued by the body that the United States, throughout the pandemic, had nominally treated as the global authority on therapeutic guidance. It was published in the official WHO living guideline. It was not a fringe finding. It was the documented conclusion of mainstream international biomedical science.

The United States did not honor it. The NCTAP payments continued. The hospital protocols continued. The administration to Medicare beneficiaries continued. By January 2021, Gilead's CEO would publicly state that approximately half of all hospitalized COVID-19 patients in the United States were receiving the drug.

The pharmacovigilance signals

Beyond the trial mortality data, the international post-marketing surveillance record was developing in parallel and in the same direction. In June 2021, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) — acting on a safety signal raised by the Italian Medicines Agency involving eleven cases of sinus bradycardia (an abnormally slow heart rhythm) — formally recommended that sinus bradycardia be added to the Veklury product information as an adverse reaction. The PRAC's stated conclusion was that "a causal relationship between the use of the medicine and this adverse event is at least a reasonable possibility." Subsequent post-marketing reports documented additional cardiac adverse events: hypotension, atrial fibrillation, QRS widening, prolonged QT interval, torsades de pointes, and cardiac arrest.

The mechanistic explanation has been published in the peer-reviewed pharmacology literature: remdesivir contains sulfobutylether-beta-cyclodextrin (SBECD) as an excipient solubilizer. SBECD is renally excreted. In patients with reduced renal function, it accumulates. The clinical trials supporting authorization had specifically excluded patients with reduced renal function. The post-approval pharmacovigilance signal of acute kidney injury indicates that, in real-world use, the drug was being administered to populations the trials had excluded.

Wu et al., Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS, 13 Frontiers in Pharmacology Article 692828 (March 25, 2022), analyzed 12,869 COVID-19 cases reported to the FDA Adverse Event Reporting System. The reporting odds ratio for acute kidney injury associated with remdesivir was 2.81, rising to 3.85 after propensity-score matching. The mean time to onset of acute kidney injury was 4.91 days from initiation of treatment — within the standard five-day course of administration.

Independent analyses of the European EudraVigilance database covering April through December 2020 identified 1,375 individual case safety reports for remdesivir, of which 416 — 30.3 percent — reported a fatal outcome. Cardiac adverse events accounted for 221 of those reports, of which 69, or 31 percent of cardiac reports, reported fatal outcomes.

This is the international record that was developing throughout the period the United States was paying hospitals to administer the drug. The signals were not hidden. They were published in the Frontiers in Pharmacology, the EMA bulletins, the WHO living guidelines. They were available on the websites of the regulators that produced them.

---

The EUA's Own Exclusion Criteria — and What Happened to Them

One detail in the Provider Fact Sheet has, in the public discussion of remdesivir, received less attention than it deserves. The FDA did not authorize remdesivir for unrestricted use. The Letter of Authorization, through the Provider Fact Sheet, identified specific exclusion criteria. Patients with severe renal impairment — defined as estimated glomerular filtration rate below 30 milliliters per minute per 1.73 square meters — were not authorized for the drug. Patients with severe hepatic dysfunction, defined by alanine aminotransferase levels greater than ten times the upper limit of normal, were not authorized for the drug. Pregnant patients were authorized only on a case-by-case determination of benefit-versus-risk.

These were not advisory recommendations. They were the bounds of the authorization itself. Administration outside those bounds was, by the express terms of the FDA's own Letter, administration outside the scope of authorized use. A drug administered to a patient meeting an EUA exclusion criterion is, in legal terms, not an authorized administration.

The pharmacovigilance signal of acute kidney injury — with its 36.45 percent case fatality among reported cases — provides the population-level confirmation that this is not a hypothetical concern. The drug was being administered, at meaningful frequency, to patients whose renal function placed them at, near, or below the EUA exclusion threshold. The renal impairment exclusion existed precisely because the drug's SBECD excipient accumulated in compromised kidneys. The FAERS signal indicates that the exclusion was, in real-world clinical practice, not consistently honored.

This matters for the legal question because it is a doctrinal hook independent of the consent question. Even if every patient had received the FDA Patient Fact Sheet, even if every patient had been told they had the option to refuse, an administration that crossed the EUA exclusion line was an administration outside the scope of authorization. The drug, in such an administration, was not the "covered countermeasure" that the Public Readiness and Emergency Preparedness Act immunizes. The legal architecture of immunity attaches only to administration in accordance with the authorization. Administration outside the authorization is administration outside the immunity.

The amicus brief filed in connection with this article argues this point in detail. The article makes the structural observation. The two together establish that the EUA framework had two distinct guardrails — the patient-information conditions and the patient-selection exclusions — and that both were systematically disregarded in real-world administration.

---

The Litigation Wall — and the Doctrinal Opening

Beginning in September 2022, families of patients who died after receiving remdesivir began filing wrongful death actions in state and federal courts. The complaints share a common factual core: administration without the FDA Fact Sheet, without disclosure of alternatives, without the patient or family being informed of the federal statutory right to refuse. The cases include Briones v. Kaiser Permanente Riverside (California), Watkins / Hamilton v. Community Regional Medical Center et al. (California), Casale v. Mountain View Hospital (Nevada), De Becker v. UHS of Delaware (Nevada), Schara v. Ascension Wisconsin (Wisconsin), Barnhart v. HealthPartners / Regions Hospital (Minnesota), Coleman v. Sharp Memorial Hospital (California), and Charles v. Northwell Health (New York), among others.

Through May 2026, no court has held that PREP Act immunity does not attach to administration that violated the conditions of authorization. The wrongful death cases have been dismissed in many instances on PREP Act preemption grounds. Some are pending; some are on appeal. The Wisconsin case Schara v. Ascension went to a jury in June 2025 and resulted in a defense verdict — but, notably, the medical battery claim was excluded from the verdict form, removing from jury consideration the one theory that would have most directly tested whether unconsented administration of an EUA product was actionable.

The defense template in these cases is uniform. The Public Readiness and Emergency Preparedness Act, 42 U.S.C. § 247d-6d, immunizes "a covered person" from "all claims for loss caused by, arising out of, relating to, or resulting from the administration to or the use by an individual of a covered countermeasure." Remdesivir is on the HHS list of covered countermeasures. Hospitals and physicians are covered persons. The willful misconduct exception, the only narrow opening in the statute, requires proof by clear and convincing evidence that the defendant acted "intentionally to achieve a wrongful purpose" with "knowledge that the action lacked legal or factual justification" and in "disregard of a known or obvious risk." The plaintiffs allege facts. The defendants move to dismiss. The cases are dismissed.

The doctrinal opening

The plaintiffs have been losing because they have been arguing on terrain the defense has fortified. The traditional plaintiff strategies — informed-consent claims as state-law exceptions to PREP Act preemption, fraud-concealment theories, willful misconduct allegations — have, with very few exceptions, failed at the motion-to-dismiss stage.

What has not been argued, and what is the doctrinal subject of the amicus brief filed in connection with this article, is the threshold scope question. The PREP Act immunizes the administration "of a covered countermeasure." The term "covered countermeasure" is defined, in 42 U.S.C. § 247d-6d(i)(1)(C), by reference to authorization "in accordance with section 564." Section 564, in turn, conditions authorization on the patient-information requirements and the exclusion criteria. Administration in violation of those conditions is, in the language of the statute itself, not authorized administration of a covered countermeasure.

This is not an argument that the PREP Act has an exception for informed-consent claims. The courts have rejected that argument, and rightly — the statute as written does not contain such an exception. The scope argument is structurally different. It is that the administration in question was never within the scope of the immunity in the first place, because the threshold definitional element — administration in accordance with Section 564 — was never satisfied.

The argument has been made possible by a Supreme Court decision that did not exist when the early PREP Act cases were decided. In June 2024, the Court decided Loper Bright Enterprises v. Raimondo, 144 S. Ct. 2244 (2024), overruling the forty-year-old Chevron doctrine that had required courts to defer to agency interpretations of ambiguous statutes. The HHS Office of General Counsel Advisory Opinions that had supplied the expansive reading of the PREP Act — Advisory Opinion 20-02 (May 19, 2020) and Advisory Opinion 21-01 (January 8, 2021) — were issued under the assumption of Chevron deference. After Loper Bright, courts must independently construe the statute, and the Advisory Opinions are entitled at most to Skidmore persuasive weight, which they do not carry given their inconsistency with the statutory text.

The Major Questions Doctrine, articulated in West Virginia v. EPA, 142 S. Ct. 2587 (2022), independently forecloses the broad construction. Where an agency claims authority to make decisions of "vast economic and political significance," courts require "clear congressional authorization." The HHS construction of the PREP Act effects a vast displacement of state common law. That displacement is not clearly authorized by the statutory text.

The constitutional architecture reinforces the conclusion. The substantive due process right recognized in Cruzan v. Director, Missouri Department of Health, 497 U.S. 261 (1990), and Washington v. Glucksberg, 521 U.S. 702 (1997), protects the right to refuse unwanted medical treatment. The Seventh Amendment guarantees civil jury trial in actions at common law. The Fifth Amendment Takings Clause prevents the federal abrogation of vested tort claims without compensation. The Tenth Amendment counsels caution in displacing state regulation of medical practice. The First Amendment protects the patient's right to receive truthful information about a medical product. Each of these constitutional concerns invokes the constitutional avoidance canon, under which courts adopt the narrower of two plausible statutory constructions where the broader would raise serious constitutional questions.

The New York doctrine of informed consent, traceable to Schloendorff v. Society of N.Y. Hospital, 211 N.Y. 125 (1914), and codified in N.Y. Public Health Law § 2805-d, provides the state-law framework. The international ethical norms articulated at Nuremberg, in Helsinki, and in the Belmont Report provide the historical and customary backdrop. The Patient Self-Determination Act and the CMS Conditions of Participation provide the parallel federal regulatory architecture. Each is a separate doctrinal source pointing in the same direction.

Together they amount to the doctrinal opening the plaintiffs in earlier cases did not have, because the post-Loper Bright framework did not exist when they filed. The window is open. The question is whether it will be used.

---

What This Looks Like as a Pattern

Let us be careful about the framing. The argument here is not that remdesivir was a deliberate poison administered with malice. The argument is more disturbing because it is more structural.

What the documentary record establishes is a system in which: (i) a drug that had failed in its prior major clinical trial was, within six days of an unfavorable international leak, repackaged through an endpoint change and announced from the Oval Office as a new standard of care; (ii) the Emergency Use Authorization that followed was conditioned by federal statute on the patient being told they had the right to refuse, and the hospitals systematically did not provide that information; (iii) the federal payment architecture (CARES Act adjustment plus NCTAP add-on) was designed in such a way that hospitals had a direct financial inducement to administer the drug to Medicare beneficiaries; (iv) the international randomized controlled trial evidence accumulating throughout 2020 indicated no statistically significant mortality benefit, and in some subgroups indicated harm, and the World Health Organization formally recommended against the drug in November 2020; and (v) the United States continued its protocol and payment architecture for nearly three additional years after that recommendation.

This is not the description of a single bad decision. It is the description of a structural failure with multiple stages, each stage building on the prior stages, each stage benefiting from the legal immunity built into the framework's foundation. The Public Readiness and Emergency Preparedness Act, written in 2005 to protect manufacturers in a future pandemic, became in 2020 the legal architecture under which the patient was the residual claimant — the party to whom risk was assigned, against whom liability was foreclosed, and from whom consent was, in many documented cases, never obtained.

This is what an emergency built without accountability looks like. It is the rational, predictable, sometimes lethal output of a financial architecture that paid for one thing and a legal architecture that protected against the consequences of that payment, with the patient — the person whose body the drug entered — placed at the bottom of the ledger as a unit of measurement rather than the subject of the inquiry.

---

The Accountability Question

In May 2026, accountability for what happened during the COVID-19 emergency is the subject of dozens of pending lawsuits, two contested doctrinal frontiers (post-Loper Bright agency deference, and the Eleventh Circuit's pending review of the qui tam False Claims Act framework in Zafirov v. Florida Medical Associates), and a slowly emerging public record of exactly what was funded, who profited, and what the patients were told.

The doctrinal opening described in Part VII is the legal vehicle. The amicus brief filed in Charles v. Northwell Health in the Supreme Court of the State of New York advances the threshold scope argument that no published court has squarely decided. The argument is not about extending the willful misconduct exception or carving out an informed-consent exception that the statute does not contain. The argument is that the immunity was never coextensive with all administration in the first place — that it attached only to administration "in accordance with section 564," and that administration in violation of Section 564's conditions is administration outside the immunity's reach.

If that argument prevails — in Charles, on appeal in Schara, in Coleman, in any of the cases that follow — the legal architecture that has, since 2020, foreclosed accountability begins to crack. The False Claims Act qui tam framework, if it survives the Eleventh Circuit's review of Zafirov, provides a parallel pathway. The federal payment architecture conditioned on lawful administration — administration that complied with the EUA conditions of authorization — is the same architecture under which non-compliance becomes potentially false-claim conduct.

None of this is automatic. None of this is assured. The doctrinal pathways are open, but they have not yet been walked. The cases are pending, but they have not yet been won.

What the documentary record shows, with a clarity that no amount of subsequent industry-funded real-world evidence studies can erase, is that the system, as it operated, did not protect the patient. It protected the manufacturer, the hospital, the regulatory architects, and the financial flows. It treated the patient as the bottom row of the ledger.

The question that runs through this entire series — through Remdesivir, through the gain-of-function funding trail, through the email files, through the orphan trials, through the regulatory architecture that traced from AZT through the parallel-track expansion to the modern Emergency Use Authorization — is whether that ordering was a temporary distortion of an otherwise sound system or whether it is what the system, as currently constructed, structurally produces.

The remdesivir record suggests the latter. The next six parts of this series will establish whether that conclusion holds across the broader pattern.

What is required, at minimum, is that the patient be told. That is what Section 564 of the Federal Food, Drug, and Cosmetic Act required. That is what the FDA's Letter of Authorization required. That is what the Patient Fact Sheet was designed to communicate. That is what New York informed-consent law has required since 1914, when Justice Cardozo wrote in Schloendorff that "[e]very human being of adult years and sound mind has a right to determine what shall be done with his own body."

The wrongful death record, from California to Wisconsin to New York, alleges that this requirement was not met. The amicus brief argues that this requirement was not met. The Federal Register entries documenting the financial architecture establish the reason it was not met.

When the documentary record speaks this clearly, the question for the courts and for the country is not whether something happened. It is whether anyone will be held to account for what the record itself describes.